Contineum Therapeutics, Inc. (CTNM) stock
CTNMNasdaqPharmaceutical PreparationsFiscal year ends December 31
$9.55−0.12 (-1.24%)
Close on Nov 17, 2026Market cap $359.28MP/E –Yield –
Contineum Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Contineum Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$53.01M. For fiscal 2025 it was -$55.31M.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$55.31M | – |
| FY2024 | Dec 31, 2024 | -$32.85M | -269.8% |
| FY2023 | Dec 31, 2023 | $19.35M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$11.50M | – |
| Q1 FY2026 | Mar 31, 2026 | -$16.27M | – |
| Q4 FY2025 | Dec 31, 2025 | -$13.04M | – |
| Q3 FY2025 | Sep 30, 2025 | -$12.20M | – |
| Q2 FY2025 | Jun 30, 2025 | -$15.66M | – |
| Q1 FY2025 | Mar 31, 2025 | -$14.41M | – |
| Q4 FY2024 | Dec 31, 2024 | -$10.20M | – |
| Q3 FY2024 | Sep 30, 2024 | -$6.17M | – |
| Q2 FY2024 | Jun 30, 2024 | -$8.50M | -120.9% |
| Q1 FY2024 | Mar 31, 2024 | -$7.98M | – |
| Q4 FY2023 | Dec 31, 2023 | -$10.70M | – |
| Q3 FY2023 | Sep 30, 2023 | -$5.38M | – |
| Q2 FY2023 | Jun 30, 2023 | $40.67M | – |
| Q1 FY2023 | Mar 31, 2023 | -$5.24M | – |
See a number that looks wrong?